Cargando…
Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs ha...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/ https://www.ncbi.nlm.nih.gov/pubmed/36187919 http://dx.doi.org/10.1016/j.csbj.2022.09.017 |
_version_ | 1784797005427507200 |
---|---|
author | Liu, Weiwei Liu, Chaoqun Wang, Hui Xu, Lijun Zhou, Jueyu Li, Sihua Cheng, Yu Zhou, Rui Zhao, Liang |
author_facet | Liu, Weiwei Liu, Chaoqun Wang, Hui Xu, Lijun Zhou, Jueyu Li, Sihua Cheng, Yu Zhou, Rui Zhao, Liang |
author_sort | Liu, Weiwei |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramatically restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mechanisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment. |
format | Online Article Text |
id | pubmed-9508382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Research Network of Computational and Structural Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-95083822022-09-30 Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy Liu, Weiwei Liu, Chaoqun Wang, Hui Xu, Lijun Zhou, Jueyu Li, Sihua Cheng, Yu Zhou, Rui Zhao, Liang Comput Struct Biotechnol J Review Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramatically restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mechanisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment. Research Network of Computational and Structural Biotechnology 2022-09-15 /pmc/articles/PMC9508382/ /pubmed/36187919 http://dx.doi.org/10.1016/j.csbj.2022.09.017 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Liu, Weiwei Liu, Chaoqun Wang, Hui Xu, Lijun Zhou, Jueyu Li, Sihua Cheng, Yu Zhou, Rui Zhao, Liang Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
title | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
title_full | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
title_fullStr | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
title_full_unstemmed | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
title_short | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
title_sort | targeting n6-methyladenosine rna modification combined with immune checkpoint inhibitors: a new approach for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/ https://www.ncbi.nlm.nih.gov/pubmed/36187919 http://dx.doi.org/10.1016/j.csbj.2022.09.017 |
work_keys_str_mv | AT liuweiwei targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT liuchaoqun targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT wanghui targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT xulijun targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT zhoujueyu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT lisihua targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT chengyu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT zhourui targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT zhaoliang targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy |